AR083287A1 - Derivados de fenoxi-piridin-3-il-benzamida - Google Patents
Derivados de fenoxi-piridin-3-il-benzamidaInfo
- Publication number
- AR083287A1 AR083287A1 ARP110103657A AR083287A1 AR 083287 A1 AR083287 A1 AR 083287A1 AR P110103657 A ARP110103657 A AR P110103657A AR 083287 A1 AR083287 A1 AR 083287A1
- Authority
- AR
- Argentina
- Prior art keywords
- fenoxi
- benzamida
- piridin
- derivatives
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente proporciona un compuesto que tiene un excelente efecto antitumoral, estabilidad y estabilidad metabólica. El compuesto de la presente está representado por la fórmula general (1) en donde R1 representa un átomo de halógeno, un grupo arilo, un grupo ariloxi o un grupo alquilo inferior opcionalmente sustituido con uno o varios átomos de halógeno; R2 representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo inferior o un grupo alcoxi inferior; y m representa un número entero de 1 a 3; siempre que, cuando m representa 2 ó 3, R1 sean iguales o diferentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38939310P | 2010-10-04 | 2010-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083287A1 true AR083287A1 (es) | 2013-02-13 |
Family
ID=44872549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103657 AR083287A1 (es) | 2010-10-04 | 2011-10-03 | Derivados de fenoxi-piridin-3-il-benzamida |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8946437B2 (es) |
| EP (1) | EP2624833B1 (es) |
| JP (1) | JP5715690B2 (es) |
| KR (1) | KR101797797B1 (es) |
| CN (1) | CN103189061B (es) |
| AR (1) | AR083287A1 (es) |
| AU (1) | AU2011313236B2 (es) |
| BR (1) | BR112013007841B1 (es) |
| CA (1) | CA2813153C (es) |
| CO (1) | CO6660459A2 (es) |
| DK (1) | DK2624833T3 (es) |
| EA (1) | EA021627B1 (es) |
| ES (1) | ES2526574T3 (es) |
| HK (1) | HK1187540A1 (es) |
| HR (1) | HRP20141237T1 (es) |
| IL (1) | IL225520A (es) |
| MX (1) | MX2013003589A (es) |
| MY (1) | MY157563A (es) |
| NZ (1) | NZ609151A (es) |
| PL (1) | PL2624833T3 (es) |
| PT (1) | PT2624833E (es) |
| RS (1) | RS53749B1 (es) |
| SG (1) | SG189146A1 (es) |
| SI (1) | SI2624833T1 (es) |
| SM (1) | SMT201500056B (es) |
| TW (1) | TWI526431B (es) |
| UA (1) | UA110037C2 (es) |
| WO (1) | WO2012046825A1 (es) |
| ZA (1) | ZA201302332B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946437B2 (en) * | 2010-10-04 | 2015-02-03 | Otsuka Pharmaceutical Co., Ltd. | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer |
| JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
| AU2020244921A1 (en) * | 2019-03-25 | 2021-09-02 | Otsuka Pharmaceutical Co., Ltd. | Antitumor composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
| PL1957073T3 (pl) * | 2005-12-05 | 2014-09-30 | Otsuka Pharma Co Ltd | Substancja lecznicza |
| UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| US8946437B2 (en) * | 2010-10-04 | 2015-02-03 | Otsuka Pharmaceutical Co., Ltd. | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer |
| AU2020244921A1 (en) * | 2019-03-25 | 2021-09-02 | Otsuka Pharmaceutical Co., Ltd. | Antitumor composition |
-
2011
- 2011-10-03 US US13/877,276 patent/US8946437B2/en active Active
- 2011-10-03 EP EP20110773326 patent/EP2624833B1/en active Active
- 2011-10-03 MY MYPI2013001147A patent/MY157563A/en unknown
- 2011-10-03 SG SG2013023148A patent/SG189146A1/en unknown
- 2011-10-03 BR BR112013007841-3A patent/BR112013007841B1/pt active IP Right Grant
- 2011-10-03 AU AU2011313236A patent/AU2011313236B2/en active Active
- 2011-10-03 AR ARP110103657 patent/AR083287A1/es unknown
- 2011-10-03 PL PL11773326T patent/PL2624833T3/pl unknown
- 2011-10-03 RS RS20150024A patent/RS53749B1/en unknown
- 2011-10-03 KR KR1020137008052A patent/KR101797797B1/ko active IP Right Grant
- 2011-10-03 CA CA2813153A patent/CA2813153C/en active Active
- 2011-10-03 ES ES11773326.1T patent/ES2526574T3/es active Active
- 2011-10-03 MX MX2013003589A patent/MX2013003589A/es active IP Right Grant
- 2011-10-03 SI SI201130409T patent/SI2624833T1/sl unknown
- 2011-10-03 CN CN201180047707.2A patent/CN103189061B/zh active Active
- 2011-10-03 TW TW100135750A patent/TWI526431B/zh active
- 2011-10-03 JP JP2013515439A patent/JP5715690B2/ja active Active
- 2011-10-03 DK DK11773326T patent/DK2624833T3/en active
- 2011-10-03 UA UAA201303865A patent/UA110037C2/uk unknown
- 2011-10-03 PT PT11773326T patent/PT2624833E/pt unknown
- 2011-10-03 EA EA201390323A patent/EA021627B1/ru unknown
- 2011-10-03 NZ NZ60915111A patent/NZ609151A/en unknown
- 2011-10-03 WO PCT/JP2011/073165 patent/WO2012046825A1/en active Application Filing
-
2013
- 2013-03-28 ZA ZA2013/02332A patent/ZA201302332B/en unknown
- 2013-04-02 IL IL225520A patent/IL225520A/en active IP Right Grant
- 2013-04-16 CO CO13097703A patent/CO6660459A2/es unknown
-
2014
- 2014-01-22 HK HK14100670.1A patent/HK1187540A1/xx unknown
- 2014-12-17 US US14/574,102 patent/US20150105432A1/en not_active Abandoned
- 2014-12-18 HR HRP20141237AT patent/HRP20141237T1/hr unknown
-
2015
- 2015-03-09 SM SM201500056T patent/SMT201500056B/xx unknown
-
2016
- 2016-11-28 US US15/362,561 patent/US20170298023A1/en not_active Abandoned
-
2018
- 2018-05-02 US US15/969,690 patent/US20180265471A1/en not_active Abandoned
-
2019
- 2019-06-13 US US16/440,924 patent/US20200031773A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/039,731 patent/US20210017134A1/en not_active Abandoned
-
2022
- 2022-12-30 US US18/148,672 patent/US20230139808A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6561817A2 (es) | Derivados de piridina di-sustituida como agentes anticancer | |
| MX2018016267A (es) | Metodo para producir derivado de piridona policiclica sustituida y cristal del mismo. | |
| JO3509B1 (ar) | معدلات p2x7 | |
| ES2635318T3 (es) | Moduladores P2X7 | |
| CU20140105A7 (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| EA201591503A1 (ru) | Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина | |
| PE20160961A1 (es) | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa) | |
| ECSP12012212A (es) | Derivados de ariletinilo | |
| MX2013011429A (es) | Novedoso compuesto de imidazo-oxazina o sal del mismo. | |
| TN2012000575A1 (en) | Compositions and methods for modulating the wnt signaling pathway | |
| BR112014005844A2 (pt) | composto orgânico, dispositivo de emisão de luz orgânico, e aparelhos de exibição | |
| CR20150268A (es) | Compuestos novedosos | |
| MY174180A (en) | Coating agent | |
| JO3143B1 (ar) | مركبات تتراهيدرو بيرولو ثيازين | |
| CO6801734A2 (es) | Derivados de etinilo como moduladores alostéricos positivos de mglur5 | |
| CR20160198A (es) | Derivados de etinilo-imidazolidín-2, 4-diona como moduladore mglur4 | |
| AR083287A1 (es) | Derivados de fenoxi-piridin-3-il-benzamida | |
| CR20160082A (es) | Nuevo derivado de triazina | |
| MX369470B (es) | Medios y método para el tratamiento de tumores sólidos. | |
| MX355415B (es) | Composiciones y metodos para tratar enfermedades y trastornos que son modulados por una vía de transducción de señales. | |
| MY170131A (en) | Tracers and method of marking hydrocarbon liquids | |
| DOP2011000296A (es) | Compuesto de pirazol | |
| IN2014DN08653A (es) | ||
| SE1100784A1 (sv) | Ny fosfatförening | |
| IN2015DN02514A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |